Crohn's Disease
8 videos · updated daily
2:10 The Missing Piece in IBD Treatment? Regenerating the Gut's Protective Barrier Shows Promise
Researchers at Calibr-Skaggs on CLF065, a potential first-in-class regenerative medicine designed to restore the epithelial barrier in inflammatory bowel disease.
23:36 PALI-2108 for Crohn's Disease and Ulcerative Colitis
Palisade Bio CEO JD Finley and CMO Dr Mitchell Jones discuss on The BioHub PALI-2108, an investigational oral PDE4 inhibitor prodrug, its Phase 1 findings in ulcerative colitis and fibrostenotic Crohn's disease, and plans for Phase 2 as of September 2026.
25:23 The Stenova Trial: A New Treatment Option with Ontunisertib in Fibrostenosing CD
Florian Rieder of Cleveland Clinic, principal investigator of the Stenova trial, on ontunisertib — an oral, gut-restricted ALK-5 inhibitor — in fibrostenosing Crohn's disease.
4:48 FUZION: Guselkumab in Perianal Crohn's Disease
Laurent Peyrin-Biroulet, MD, PhD, discusses with HCPLive Phase 3 FUZION results for guselkumab in perianal fistulizing Crohn's disease, including combined fistula remission at 24 weeks and safety.
8:36 VIVID-2: Mirikizumab in Crohn's Disease at Three Years
Edward Barnes, MD, MPH, of the University of North Carolina at Chapel Hill discusses with HCPLive three-year results from the ongoing VIVID-2 extension study of mirikizumab in moderate-to-severe Crohn's disease.
13:20 VOLTAIRE-CD: Biosimilar BI 695501 vs Adalimumab
Professor Stephen Hanauer presents for the Video Journal of Biomedicine results from the Phase III VOLTAIRE-CD study comparing the safety and efficacy of the biosimilar BI 695501 with adalimumab in Crohn's disease.
22:10 Crohn's & Colitis Foundation on Recruiting Patients for IBD Trials
Gastroenterologist Chung Sang Tse and the Crohn's & Colitis Foundation discuss how the ADEPT trial recruited adults with inflammatory bowel disease, and which recruitment methods actually worked.
53:59 IBD Research and How You Can Take Part
Jordan Axelrad, MD, MPH, director of clinical and translational research at NYU Langone Health's IBD Center, joins the Crohn's & Colitis Foundation's Clinical Trials Ambassadors on how those with Crohn's disease or ulcerative colitis can take part in research.